Skip to main content

Advertisement

Log in

Strategies in Stable Ischemic Heart Disease: Lessons from the COURAGE and BARI-2D Trials

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

There is a continuing debate regarding the most effective strategy for treating stable ischemic heart disease (SIHD). Conflicting data have emerged from several small, randomized controlled trials and meta-analyses regarding the benefits of early revascularization in SIHD. Two recent multicenter, randomized trials, the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial and the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI-2D) trial, compared two management strategies in SIHD—an initial conservative approach with optimal medical therapy (OMT) versus a strategy of early revascularization in combination with OMT. COURAGE randomized SIHD patients who were candidates for percutaneous coronary intervention (PCI) to either a strategy of early PCI in combination with OMT or OMT alone, whereas BARI-2D randomized diabetic patients with coronary artery disease to either early revascularization (PCI or coronary artery bypass surgery [CABG]) versus OMT. This review examines the principal findings of these trials, with discussion of their strengths, limitations, and applicability to the general population. The results support the hypothesis that in patients with SIHD, early revascularization with PCI in combination with OMT is not superior to OMT alone in reducing mortality and other major cardiovascular events. Subset analysis from BARI-2D did suggest that early CABG, although it did not reduce mortality, significantly reduced the rate of nonfatal myocardial infarction compared with an initial OMT approach. Based on these data, the majority of patients with SIHD should be managed initially with medical therapy, a strategy that is also the most cost effective. Revascularization can be considered for patients with severe or refractory symptoms despite a trial of medical therapy. For diabetic patients who have extensive coronary artery disease, early revascularization with CABG may be reasonable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13–20.

    Article  PubMed  Google Scholar 

  2. Antman EM, Armstrong PW, Bates ER, et al.: 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008, 117:296–329.

    Article  PubMed  Google Scholar 

  3. Mehta SR, Cannon CP, Fox KA, et al.: Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005, 293:2908–2917.

    Article  CAS  PubMed  Google Scholar 

  4. American College of Cardiology National Cardiovascular Data Registry. Available at http://www.ncdr.com/WebNCDR/Common/. Accessed June 2, 2010.

  5. • Boden WE, O’Rourke RA, Teo KK, et al.: Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007, 356:1503–1516. This article is the first publication from the COURAGE trial demonstrating the absence of incremental benefit of early PCI over OMT in overall survival rate.

    Article  CAS  PubMed  Google Scholar 

  6. • The BARI 2D Study Group: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503–2515. This article is the first publication from the BARI-2D trial demonstrating the absence of incremental benefit of early revascularization (PCI and CABG) over OMT in overall survival rate. The early CABG group demonstrated reduced nonfatal MI over the OMT group.

    Google Scholar 

  7. Henderson RA, Pocock SJ, Clayton TC, et al.: Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003, 42:1161–1170.

    Article  PubMed  Google Scholar 

  8. TIME Investigators: Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001, 358:951–957.

    Article  Google Scholar 

  9. Hueb W, Soares PR, Gersh BJ, et al.: The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 2004, 43:1743–1751.

    Article  PubMed  Google Scholar 

  10. RITA-2 trial participants: Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997, 350:461–468.

    Article  Google Scholar 

  11. Hueb W, Lopes, NH, Gersh BJ, et al.: Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007, 115:1082–1089.

    Article  PubMed  Google Scholar 

  12. • Katritsis DG, Ioannidis JP: Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005, 111:2906–2912. This article is an important meta-analysis published prior to the release of COURAGE and BARI-2D data that directly compared the utility of early revascularization versus medical therapy in SIHD patients.

    Article  PubMed  Google Scholar 

  13. Boden WE, O’Rourke RA, Teo KK, et al.: The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol 2007, 99:208–212.

    Article  PubMed  Google Scholar 

  14. Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047–1053.

    Article  Google Scholar 

  15. Garcia MJ, McNamara PM, Gordon T, et al.: Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974, 23:105–111.

    CAS  PubMed  Google Scholar 

  16. Gibbons RJ, Abrams J, Chatterjee K, et al.: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003, 107:149–158.

    Article  PubMed  Google Scholar 

  17. Fox K, Garcia MA, Ardiddino D, et al.: Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006, 27:1341–1381.

    Article  PubMed  Google Scholar 

  18. Cecil WT, Kasteridis P, Barnes JW Jr, et al.: A meta-analysis update: percutaneous coronary interventions. Am J Manag Care 2008, 14:521–528.

    PubMed  Google Scholar 

  19. • Schomig A, Mehilli J, de Waha A, et al.: A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol 2008, 52:894–904. This article is a large meta-analysis on therapeutic approaches of stable CAD patients. It demonstrated that PCI is associated with significant mortality reduction compared with medical therapy.

    Article  PubMed  Google Scholar 

  20. Hochman JS, Lamas GA, Buller CE, et al.: Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006, 355:2395–2407.

    Article  CAS  PubMed  Google Scholar 

  21. • Wijeysundera HC, Ko DT: Does percutaneous coronary intervention reduce mortality in patients with stable chronic angina: are we talking about apples and oranges? Circ Cardiovasc Qual Outcomes 2009, 2:123–126. This article analyzed the review by Schomig et al. [19•] and suggested that inclusion of unstable CAD patients in the analysis may have contributed to the improved outcome seen with PCI.

    Article  PubMed  Google Scholar 

  22. Hlatky MA, Boothroyd DB, Melsop KA, et al.: Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation 2009, 120:2550–2558.

    Article  PubMed  Google Scholar 

  23. Naghavi M, Libby P, Falk E, et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664–1672.

    Article  PubMed  Google Scholar 

  24. Pfisterer M, Buser P, Osswald S, et al.: Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003, 289:1117–1123.

    Article  PubMed  Google Scholar 

  25. Pfisterer M, and Trial of Invasive versus Medical therapy in Elderly patients Investigators: Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). Circulation 2004, 110:1213–1218.

    Article  PubMed  Google Scholar 

  26. Valgimigli M, Serruys PW, Tsuchida K, et al.: Cyphering the complexity of coronary artery disease using the syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. Am J Cardiol 2007, 99:1072–1081.

    Article  PubMed  Google Scholar 

  27. Hachamovitch R, Hayes SW, Friedman JD, et al.: Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003, 107:2900–2907.

    Article  PubMed  Google Scholar 

  28. Shaw LJ, Berman DS, Maron DJ, et al.: Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008,117:1283–1291.

    Article  PubMed  Google Scholar 

  29. Nissen SE, Nicholls SJ, Sipahi I, et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556–1565.

    Article  CAS  PubMed  Google Scholar 

  30. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071–1080.

    Article  CAS  PubMed  Google Scholar 

  31. Jensen LO, Thayssen P, Pedersen KE, et al.: Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 2004, 110:265–270.

    Article  CAS  PubMed  Google Scholar 

  32. Farkouh ME, Dangas G, Leon MB, et al.: Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J 2008, 155:215–223.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Dr. Boden has been a consultant for Gilead Scientific. His institution has received grants from Abbott Laboratories, Gilead Scientific, and Sanofi-Aventis. He has been on the speakers’ bureau of Gilead Scientifc and Sanofi-Aventis, and has had travel expenses paid for by Abbott Laboratories, Bristol-Myers Squibb, and Gilead Scientific. No other potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to William E. Boden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fernandez, S.F., Boden, W.E. Strategies in Stable Ischemic Heart Disease: Lessons from the COURAGE and BARI-2D Trials. Curr Atheroscler Rep 12, 423–431 (2010). https://doi.org/10.1007/s11883-010-0135-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-010-0135-2

Keywords

Navigation